Canton Strategic Holdings closed at $2.16 on Nov 4, up 10.77%, 57.9% below its highest close since Feb 18. Volume of 512.8K shares was 0.69× its 20-day average (below normal).
Split-adjusted performance: -7.7% over one month.
In the quarter ended Jun 30, 2026, revenue was $1.50M, with a net margin of -1287.2%.
Short interest was 8.0M shares at the Oct 15 settlement, up 2.7% from the prior report (10.6% of float, 10.2 days to cover).
No reported quarters with price history yet.
Percentile among 435 companies (100 = best)
Industry medians: 6-month return +7.4%, revenue growth +5.2%, net margin 18.2%, P/E 12.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CNTNCanton Strategic Holdings | $2.16 | +10.77% | — | — | −1287.2% | — | $172.1M | |
| EBMTEagle Bancorp Montana | $21.44 | +1.66% | −5.5% | −1.0% | 11.7% | 10.6 | $170.8M | Compare |
| WAFDPWaFd, Inc. Depositary Shares | $14.73 | +1.59% | −11.8% | +1.8% | 17.5% | 0.7 | $176.8M | Compare |
| HNVRHanover Bancorp | $23.01 | +0.35% | −1.2% | −2.1% | 11.4% | 18.0 | $167.0M | Compare |
| USBCUSBC | $0.4290 | +3.55% | +9.0% | — | — | — | $166.5M | Compare |
| TONXTON Strategy | $2.90 | +1.40% | −9.1% | — | 511.0% | — | $159.7M | Compare |
| BAFNBayFirst Financial | $5.97 | +1.36% | −16.9% | −70.9% | −345.9% | — | $185.5M | Compare |
| FGBIFIRST GUARANTY BANCSHARES | $11.29 | +7.32% | +20.5% | −5.8% | 5.4% | — | $187.8M | Compare |
| FINWFinWise Bancorp | $13.67 | +4.51% | +0.6% | +98.1% | 3.6% | 13.5 | $187.9M | Compare |
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
